Skip to content

Effects of Fasting-Mimicking Diet on Central and Peripheral Components of Fatigue, Muscular Resistance

Effects of Fasting-mimicking Diet on Central and Peripheral Components of Fatigue, Muscular Resistance

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04476615
Acronym
FMD_Exercise
Enrollment
24
Registered
2020-07-20
Start date
2017-12-04
Completion date
2020-01-16
Last updated
2020-07-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diet, Healthy, Fasting, Fatigue, Mental, Fatigue; Muscle, Heart

Keywords

fatigue, fasting-mimicking diet, healthy, young adults, exercise

Brief summary

The aim of the study is to test a Fasting Mimicking Diet (FMD) for its efficacy on improving muscular resistance and endurance. The investigators will perform a randomized clinical trial to test the efficacy of the FMD on improving muscular strength, muscular resistance and endurance in physically active young adults (18-40 years of age). The study will include two arms: Placebo (Placebo diet) and FMD (3 cycles of 5-day fasting-mimicking diet within two months). Study endpoints will include muscular strength evaluation of lower limbs, cardio-pulmonary responses, neuromuscular function and muscle architecture. Subjects will be evaluated 4 times within 3 months: at baseline (T1), after the 1st cycle of diet (T2), 7 to 15 days after the 3rd cycle of diet maintaining baseline intensity (T3) and with re-assessment of Peak Power Output (T4).

Interventions

DIETARY_SUPPLEMENTFasting-Mimicking Diet (ProLon®)

Dietary restriction: Fasting-Mimicking Diet (ProLon®). 5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total).

DIETARY_SUPPLEMENTPlacebo bars

Dietary supplementation: Low-energy bars (L-Nutra®) to integrate the daily nutritional habits - one bar per day. 5-days cycles spaced at 1-month intervals for 3 months (3 cycles in total).

Sponsors

University of Southern California
CollaboratorOTHER
Universita di Verona
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
18 Years to 40 Years
Healthy volunteers
Yes

Inclusion criteria

* Male sex; * Age Range: 18-40 years old; * Body Mass Index (BMI) range between 18.5 and 30; * METs minutes per week - calculated by International physical activity questionnaire (IPAQ) - between 600 and 3000.

Exclusion criteria

* Female sex; * History of muscle, joints and nerves injuries to the upper and/or lower limbs in the previous 12 months; * Body Mass Index (BMI) below 18.5 and above 30; * METs minutes per week - calculated by International physical activity questionnaire (IPAQ) - below 600 or above 3000.

Design outcomes

Primary

MeasureTime frameDescription
Change in median frequency of the power spectrum density of EMGduring the performance test at each time point: baseline (T1); day 5 (1°diet cycle - T1), after 2 months (T3 and T4)EMG signal from the vastus lateralis (VL) muscle was recorded throughout exercise to estimate the output of spinal motoneurons and the development of peripheral fatigue.
Change in resting twitch force (RT)baseline (T1); day 5 (1°diet cycle - T1), after 2 months (T3 and T4)Force elicited at rest by electrical stimulation of the femoral nerve, considering for lever length \[N\*m\].
Change in oxygen consumption (VO2)baseline (T1); day 5 (1°diet cycle - T1), after 2 months (T3 and T4)Variations of mean oxygen consumption at rest and at each minute while exercising (performance test).
Change in peak (task-specific) oxygen consumption (VO2)baseline (T1) and after 2 months (T4).Peak oxygen consumption during the incremental test (maximal value during a 30 time-window).
Change in femoral (artery) blood flow (FBF)at rest and during the performance test. Differences between each time point will be assessed: baseline (T1); day 5 (1°diet cycle - T1), after 2 months (T3 and T4)Measurements of common femoral arterial blood velocity (Vmean) and vessel diameter will be performed using ultrasound Doppler, distal to the inguinal ligament and proximal to the bifurcation of the deep and superficial femoral arteries. (FBF = Vmean p (vessel diameter/2)\^2 \* 60)
Difference in time to exhaustion (TTE)baseline (T1); day 5 (1°diet cycle - T1), after 2 months (T3 and T4)Difference between time points in time duration \[s\] of the exercise at a given power output (85%) and cadence (60 RPM), before the given work rate could not be sustained.
Change in maximal voluntary contraction (MVC)baseline (T1); day 5 (1°diet cycle - T1), after 2 months (T3 and T4)Variation between time points in maximal force voluntarily produced by the knee extensor muscles pre- and immediately post exercise, considering for lever length \[N\*m\].
Change in voluntary (muscle) activation (VA)baseline (T1); day 5 (1°diet cycle - T1), after 2 months (T3 and T4)Change between time points in the percentage of muscle activated by volition. \[%\] To quantify voluntary activation, the amplitude of the superimposed twitch is expressed as a fraction of the twitch evoked by the same stimulus in the relaxed muscle.

Secondary

MeasureTime frameDescription
Change in minute ventilation (VE)baseline (T1); day 5 (1°diet cycle - T1), after 2 months (T3 and T4)Difference in ventilatory response at rest and while exercising measured by a breath-by-breath system \[L/min\].
Change in heart rate (HR)baseline (T1); day 5 (1°diet cycle - T1), after 2 months (T3 and T4)Difference in the cardiac response at rest and while exercising measured by a heart rate monitor system.
Change in Peak Power Output (Wpeak)baseline (T1) and after 2 months (T4).Difference in maximal power \[Watts\] achieved (last completed 1-min step) during the incremental test sessions.
Change in carbon dioxide (VCO2) productionbaseline (T1); day 5 (1°diet cycle - T1), after 2 months (T3 and T4)Variation of physiological production of CO2 at rest and while exercising measured by a breath-by-breath system \[L/min\].

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026